| Marc Buyse | Affiliations of authors: Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands (CJAP); International Drug Development Institute, Louvain-la-Neuve, Belgium (MB); Clinic for Oncology and Hematology, Oldenburg Clinic, Oldenburg, Germany (CHK); Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, Medical Faculty of Mannheim, University of Heidelberg, Heidelberg, Germany (PH); Unit of Medical Oncology, Riuniti Hospital, Bergamo, Italy (RL); Department of Hematology and Oncology, Martin Luther University, Halle, Germany (HJS); Department of Surgery, University Hospital, SE 751 85 Uppsala, Sweden (LP); Department of Medical Oncology, S. Martino Hospital, Genova, Italy (AS); Center R. Gauducheau 44805 Nantes-St Herblain, France (JYD)
| 000E72
| Affiliations of authors: Peter MacCallum Cancer Centre, Melbourne, Australia (PF); Australian New Zealand Breast Cancer Trials Group, Newcastle, Australia (PF); International Breast Cancer Study Group, Bern, Switzerland (PF); Irish Clinical Oncology Research Group, Dublin, Ireland (JC); Hospital of Prato, Prato, Italy (ADL); International Drug Development Institute, Louvain-la-Neuve, Belgium (MB); Grupo Espaol de Investigacion en Cancer de Mama, Madrid, Spain (AB); Hospital Arnau de Vilanova, Lleida, Spain (AB); Danish Breast Cancer Cooperative Group, Copenhagen, Denmark (MA); Swedish Breast Cancer Group, Universitetssjukhuset, Linkoping, Sweden (BN); National Institute of Oncology, Budapest, Hungary (IL); Austrian Breast and Colorectal Cancer Study Group, Vienna Medical School, Vienna, Austria (RJ); Sandton Oncology Centre, Johannesburg, South Africa (DV); Grupo Oncologico Cooperativo Chileno De Investigacion, Clinica Las Condes, Santiago, Chile (JG); Mount Hospital, Perth, Australia (GvH); Breast European Adjuvant Studies Team, Jules Bordet Institute, Brussels, Belgium (SD, SJ, MPG); sanofi-aventis, Paris, France (BB); International Breast Cancer Study Group (IBCSG), Statistical Centre and Dana Farber Cancer Institute, Boston, MA (RDG); IBCSG Scientific Committee, European Institute of Oncology, Milan, Italy (AG); IBCSG Coordinating Centre and Inselspital, Bern, Switzerland (MCG)
| 001987
| Functional Genomics and Translational Research Unit (CS, SL, BH-K, CD), Translational Research and Medical Oncology Unit (CS, CD, DL, FC, MP), Jules Bordet Institute, Machine Learning Group (BH-K), Université Libre de Bruxelles, Brussels, Belgium; National Center of Competence in Research Molecular Oncology, Swiss Institute of Experimental Cancer Research (PW, PF, MD), Swiss Institute of Bioinformatics (PW, PF, VP, MD), CH-1066 Epalinges, Switzerland; Molecular Oncology Laboratory and Molecular Angiogenesis Laboratory, Cancer Research UK and the Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (AH, SF); Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden (JS, JB); Department of Pathology, Uppsala University Hospital, Uppsala, Sweden (HN); Division of Diagnostic Oncology (HP, MJVdV), Division of Radiation Oncology (DN), The Netherlands Cancer Institute, Amsterdam, The Netherlands; International Drug Development Institute, Brussels, Belgium (MB)
| 000C21
| International Drug Development Institute, Brussels, Belgium (MB, MA, FP); Institut Jules Bordet, Brussels, Belgium (SL, CS, FC, MJP); Netherlands Cancer Institute, Amsterdam, The Netherlands (LvV, ER); European Institute of Oncology and University of Milan School of Medicine, Milan, Italy (GV); National Center of Competence in Research Molecular Oncology, Swiss Institute of Experimental Cancer Research, Epalinges & the Swiss Institute of Bioinformatics, Lausanne, Switzerland (MD); Agendia B.V. Amsterdam, The Netherlands (LvV, AMG, AF); Institut Gustave Roussy, Villejuif, France (MSd'A); Karolinska Institute, Stockholm, Sweden (JB); Centre René Huguenin and Institut National de la Santé et de la Recherche Médicale, St Cloud, France (RL); Guy's Hospital, London, U.K. (PE); John Radcliffe Hospital, Oxford, U.K. (AH); European Organisation for the Research and Treatment of Cancer Data Center, Brussels, Belgium (JB, PT)
| 000F08
| International Drug Development Institute, Louvain-la-Neuve, Belgium and Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium
| 000D93
| NONE
| 000C21
000D93
000E72
000F08
001987
|
|
|---|
